Carl Zeiss Meditec AG Revises Revenue and EBIT Forecast for FY 2023/24

Carl Zeiss Meditec AG has lowered its revenue and EBIT forecasts for FY 2023/24. The decision follows a slower recovery in its equipment business than expected. As of May 31, 2024, the preliminary revenue was €1,258 million, a 3% decline from the previous year. Preliminary EBIT was €135 million, a 26% drop.

The revised revenue forecast is now around €2,000 million, excluding contributions from the DORC acquisition. EBIT is projected to fall between €215 million and €265 million, below the former target of €348.1 million. The equipment business continues to suffer from a restrictive investment climate, especially in North America.

To adjust, the company will reduce operating expenses, notably in sales, marketing, and R&D. A further update will be provided with Q3 results on August 6, 2024. Carl Zeiss Meditec targets renewed growth in FY 2024/25 with new product launches.